98%
921
2 minutes
20
This retrospective study investigated the impact of socioeconomic status (SES) on patients at high risk of cardiovascular disease, focusing on obstructive coronary artery disease (CAD) presence and long-term cardiovascular outcomes in individuals undergoing invasive coronary angiography (ICA). Analyzing data from 9530 patients categorized by health insurance type (medical aid beneficiaries (MABs) as the low SES group; national health insurance beneficiaries (NHIBs) as the high SES group), this research explores the relationship between SES and outcomes. Despite a higher prevalence of cardiovascular risk factors, the MAB group exhibited similar rates of obstructive CAD compared to the NHIB group. However, over a median 3.5-year follow-up, the MAB group experienced a higher incidence of composite cardiovascular events, including cardiac death, acute myocardial infarction, coronary revascularization, and ischemic stroke, compared with the NHIB group (20.2% vs. 16.2%, 0.001). Multivariable Cox regression analysis, adjusting for potential confounders, revealed independently worse clinical outcomes for the MAB group (adjusted odds ratio 1.28; 95% confidence interval 1.07-1.54; = 0.006). Despite comparable CAD rates, this study underscores the fact that individuals with low SES encounter an elevated risk of composite cardiovascular events, emphasizing the association between socioeconomic disadvantage and heightened susceptibility to cardiovascular disease, even among those already at high risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815423 | PMC |
http://dx.doi.org/10.3390/healthcare12020228 | DOI Listing |
Reproduction
September 2025
Igyxos Biotherapeutics, Centre INRAE Val de Loire, Nouzilly, F-37380, France.
In Brief: Treatment of female and male infertility currently depends on repeated injections of gonadotrophins, which can be burdensome for patients and does not always provide successful outcomes. Based on different animal models, CF12 mAb potentiates the effect of both exogenous and endogenous gonadotrophins in females and males, suggesting its potential to improve outcomes and reduce the burden of infertility treatments.
Abstract: Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are key for folliculogenesis and spermatogenesis and play a role, together with chorionic gonadotrophin (CG), in fertility treatment.
Biotechnol J
September 2025
Cell Engineering Group, NIBRT, Dublin, Ireland.
Recent bulk analysis of Chinese hamster ovary (CHO) cell mitochondrial DNA revealed widespread heteroplasmy across cell lines and even within clones of the same parental host. To address this, we applied our previously developed single-cell mtDNA sequencing (scmtDNAseq) method to 84 single CHO cells. We identified widespread intercellular heteroplasmy across the CHO cell population and predicted possible phenotypic impacts.
View Article and Find Full Text PDFTransplant Cell Ther
August 2025
Division of Blood and Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Stanford, CA. Electronic address:
Background: Autologous stem cell transplantation (ASCT) remains a standard component of frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). CD38 monoclonal antibodies (mAbs), such as daratumumab and isatuximab, have been incorporated into induction regimens and are associated with deeper responses. However, their impact on hematopoietic stem cell mobilization is unclear, particularly in real-world practice.
View Article and Find Full Text PDFCephalalgia
August 2025
Department of Neurology, NeuroClinic Norway, Lillestrom, Norway.
BackgroundThe discovery of calcitonin gene-related peptide (CGRP) as a key player in migraine pathophysiology has revolutionized the approach to preventive treatment. Atogepant, an oral small-molecule CGRP receptor antagonist, has shown promising efficacy in randomized controlled trials (RCTs) for both episodic and chronic migraine. However, real-world evidence, particularly in individuals with chronic migraine and multiple preventive treatment failures, remains limited.
View Article and Find Full Text PDFERJ Open Res
July 2025
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Background: The relationship between pre-treatment levels of blood eosinophil count (BEC), fractional exhaled nitric oxide ( ) and sputum eosinophils (Sp-EOS) and treatment response to monoclonal antibodies (mAbs) in severe eosinophilic asthma (SEA) remains unclear. We evaluated pre-treatment levels of BEC, , Sp-EOS and their combinations as predictors of treatment responses in patients with SEA undergoing anti-interleukin (IL)-5/IL-5Rα or anti-IL-4Rα antibody therapies.
Methods: The study included 153 adult patients with SEA (59 anti-IL-5/IL-5Rα and 94 anti-IL-4Rα users).